Fatima Karzai, M.D.

Senior Clinician

Genitourinary Malignancies Branch

NCI/CCR

Building 10, Room 13N240
Bethesda, MD 20892

301-480-8870

fatima.karzai@nih.gov

Research Topics

As NCI Deputy Clinical Director, Dr. Karzai is passionate about patient care and clinical research. Dr. Karzai's research is focused on novel combination therapies in prostate cancer, particularly with immunotherapeutic agents such as immune checkpoint blocking antibodies and agents targeting defects in DNA damage repair pathways. Dr. Karzai is the Medical Director of the NCI Prostate Cancer Multidisciplinary Clinic and an Adjunct Investigator in the NCI Center for Immuno-Oncology. The Genitourinary Malignancies Branch enrolls patients onto clinical trials in all stages of prostate cancer.

Biography

Dr. Karzai received her M.D. from The George Washington University School of Medicine and Health Sciences in Washington, DC where she also completed her Internal Medicine residency. She completed her fellowship in Medical Oncology and Hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI) at NIH. Upon completion of her fellowship, she continued her work with the Genitourinary Malignancies Branch at the NCI as Principal Investigator of prostate cancer clinical trials. She is now a Senior Clinician in GMB and the Deputy Clinical Director for NCI. In her spare time, Dr. Karzai enjoys art, design and traveling.

Selected Publications

  1. Gandhy SU, Karzai FH, Bilusic M, McMahon S, Cordes LM, Marte J, Weisman AJ, Perk TG, Lindenberg L, Mena E, Turkbey B, Arlen PM, Dahut WL, Figg WD, Choyke P, Gulley JL, Madan RA. Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. Eur Urol Oncol. 2024;7(4):735-741.
  2. Gatti-Mays ME, Tschernia NP, Strauss J, Madan RA, Karzai FH, Bilusic M, Redman J, Sater HA, Floudas CS, Toney NJ, Donahue RN, Jochems C, Marté JL, Francis D, McMahon S, Lamping E, Cordes L, Schlom J, Gulley JL. A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. Oncologist. 2023;28(4):364-e217.
  3. Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee MJ, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer. BJU Int. 2021;127(4):435-444.
  4. Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, Trepel JB, Yuno A, Lipkowitz S, Nair J, McCoy A, Lee JM. A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer. Oncologist. 2020;25(12):1013-e1824.

Related Scientific Focus Areas

This page was last updated on Thursday, September 24, 2026